These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 28287204)

  • 1. [Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.].
    Vavassori A; Lanza P; Izzo I; Casari S; Odolini S; Zaltron S; Festa E; Castelli F
    Recenti Prog Med; 2017 Feb; 108(2):98-100. PubMed ID: 28287204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
    Johnson TM; Sison R; Fallon JP; Shukla PP; Bhattarai S; Galang H; Habeeb R; Slim J
    HIV Clin Trials; 2016 Nov; 17(6):242-245. PubMed ID: 27846791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.
    Courbon E; Laylavoix F; Soulié C; Le Beller C; Calvez V; Katlama C; Peytavin G
    J Antimicrob Chemother; 2012 Jan; 67(1):250-1. PubMed ID: 22025582
    [No Abstract]   [Full Text] [Related]  

  • 5. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
    Parisi SG; Loregian A; Andreis S; Nannetti G; Cavinato S; Basso M; Scaggiante R; Dal Bello F; Messa L; Cattelan AM; Palù G
    Int J Infect Dis; 2016 Aug; 49():151-3. PubMed ID: 27378577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.
    Esposito I; Labarga P; Barreiro P; Fernandez-Montero JV; de Mendoza C; Benítez-Gutiérrez L; Peña JM; Soriano V
    Expert Opin Drug Saf; 2015; 14(9):1421-34. PubMed ID: 26212044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In HIV-HCV co-infection check for drug interactions].
    Neumaier J
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259910
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing treatment in HIV/HCV coinfection.
    Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
    Barrail-Tran A; Goldwirt L; Gelé T; Laforest C; Lavenu A; Danjou H; Radenne S; Leroy V; Houssel-Debry P; Duvoux C; Kamar N; De Ledinghen V; Canva V; Conti F; Durand F; D'Alteroche L; Botta-Fridlund D; Moreno C; Cagnot C; Samuel D; Fougerou-Leurent C; Pageaux GP; Duclos-Vallée JC; Taburet AM; Coilly A
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1555-1563. PubMed ID: 31384986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
    Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
    Cattaneo D; Riva A; Clementi E; Milazzo L; Gervasoni C
    Ther Drug Monit; 2016 Jun; 38(3):285-7. PubMed ID: 26919548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
    Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
    El-Sherif O; Khoo S; Solas C
    Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions in HIV-infected patients treated for hepatitis C.
    Soriano V; Labarga P; Fernandez-Montero JV; Mendoza C; Benítez-Gutiérrez L; Peña JM; Barreiro P
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):807-816. PubMed ID: 28689442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
    Young B; Squires KE; Ross LL; Santiago L; Sloan LM; Zhao HH; Wine BC; Pakes GE; Margolis DA; Shaefer MS;
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):350-8. PubMed ID: 23039030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
    J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.